HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Longitudinal analysis of heart and liver iron in thalassemia major patients according to chelation treatment.

Abstract
Iron chelators and nuclear magnetic resonance imaging (MRI) techniques for assessing iron loading in liver and heart have greatly improved survival of thalassemic patients suffering iron overload-associated cardiomyopathy. However, the correlation between liver iron concentration and myocardial siderosis is ambiguous. Using an objective metric of time delay, scientists have demonstrated a lag in the loading and unloading of cardiac iron with respect to that of the liver. In the present study, we further tested this hypothesis with different chelation treatments. We analyzed the effect of three chelating treatment approaches on liver and cardiac iron content in 24 highly compliant patients who underwent 3 or more MRIs under each chelation treatment. Of the 84 MRIs considered, 32 were performed on deferoxamine (DFO - 8 patients), 24 on deferiprone (DFP - 7 patients), and 28 on combined therapy (DFO+DFP - 9 patients). In patients treated with DFO, changes in cardiac iron significantly lagged changes in liver iron but the opposite pattern was observed in patients treated with DFP (p=0.005), while combined therapy showed a pattern in-between DFO and DFP. We conclude that the temporality of changes of cardiac and liver iron is chelator-dependent, so that chelation therapy can be tailored to balance iron elimination from the liver and the heart.
AuthorsF Danjou, R Origa, F Anni, L Saba, S Cossa, G Podda, R Galanello
JournalBlood cells, molecules & diseases (Blood Cells Mol Dis) Vol. 51 Issue 3 Pg. 142-5 (Oct 2013) ISSN: 1096-0961 [Electronic] United States
PMID23816436 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
CopyrightCopyright © 2013 Elsevier Inc. All rights reserved.
Chemical References
  • Iron Chelating Agents
  • Iron
Topics
  • Adult
  • Chelation Therapy
  • Humans
  • Iron (metabolism)
  • Iron Chelating Agents (therapeutic use)
  • Iron Overload (diagnosis, drug therapy, etiology)
  • Liver (metabolism, pathology)
  • Magnetic Resonance Imaging
  • Myocardium (metabolism, pathology)
  • Young Adult
  • beta-Thalassemia (complications)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: